Maxx Orthopedics, Inc.
$563.7K 215 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aesculap Biologics, LLC
Aesculap Biologics, LLC reported $559,553.79 across General Payments, Research, and Ownership to 11 physicians and teaching hospitals across 92 transactions.
- $559.6K Above-median payer
- All-tracks total
- 92 Below-median volume
- Transactions
- 11 Below-median reach
- Recipients
- +$528.24
- General Payments vs PY2023
Aesculap Biologics, LLC reported $559,553.79 across all CMS Open Payments tracks (General + Research + Ownership) to 11 physicians and teaching hospitals in Program Year 2024 - ranking #738 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,246.07, averaging $50.9K per recipient.
How Aesculap Biologics, LLC's $559.6K all-tracks total breaks down
Aesculap Biologics, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
15/100
Total payments
F
15/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aesculap-biologics-llc Aesculap Biologics, LLC
$559.6K · #738/1,925 · 0.0% industry · PY2024
- TOT $559.6K
- RANK #738
- SHARE 0.0%
- TXN 92
- RCP 11
- CAT 2
- GEN $5.2K
- ΔGEN +$528.24
- TOP1 85.8%
- PY 2024
Volume peers
Nearest volume peer: Maxx Orthopedics, Inc. ($563.7K)
Aesculap Biologics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aesculap Biologics, LLC's CMS-reported General Payments increased by $528.24 (+11.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AESCULAP BIOLOGICS, LLCPY2023: AESCULAP BIOLOGICS, LLCPY2024: Aesculap Biologics, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,717.83
- PY2024
- $5,246.07
What the Data Shows for Aesculap Biologics, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Aesculap Biologics, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
3 transactions worth $4.5K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 85.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Aesculap Biologics, LLC's 2-category general-payment breakdown at $4.5K, 85.8% of the reported total.
How Aesculap Biologics, LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $4.5K | 3 | 85.8% |
| Food and Beverage | $746.07 | 8 | 14.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,012.43 (95.5%) of $5,246.07 in this company's General Payments records across 8 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aesculap Biologics, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Michael Bauer
$4,500.00 across 3 reported transactions
- 2
Brian Cole
$237.14 across 2 reported transactions
- 3
Kevin Plancher
$110.19 across 1 reported transactions
- 4
Jason Dragoo
$82.55 across 1 reported transactions
- 5
Kenneth Zaslav
$82.55 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aesculap Biologics, LLC ranks #738 of 1,925 by total payments (top 38% by spend) but is notably more concentrated than that alone would suggest -- #210 of 1,838 by HHI (top 11% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- GenBioPro, Inc. : $49.5K total payments, HHI 7570
- Preceptis Medical, Inc. : $60.6K total payments, HHI 7566
- UCB Biosciences Inc. : $16.7K total payments, HHI 7541
- Siesta Medical, Inc. : $19.1K total payments, HHI 7498
- Innovative Medical Products, Inc. : $22.8K total payments, HHI 7434
- Teleflex Medical Incorporated : $268.8K total payments, HHI 7395
- Aesculap Biologics, LLC (this company) : $5.2K total payments, HHI 7394
- Sequence LifeScience, Inc : $194.5K total payments, HHI 7391
- Elekta, Inc. : $3.2M total payments, HHI 7371
- Nanovis LLC : $47.0K total payments, HHI 7351
- Atrility Medical, Inc. : $712.50 total payments, HHI 7341
- Dimension Inx Corp : $1.2K total payments, HHI 7329
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aesculap Biologics, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aesculap Biologics, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aesculap Biologics, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Hu-Friedy Mfg. Co., LLC
$554.1K 2,442 recipients
Compare payment profiles
CTL Medical Corporation
$565.3K 315 recipients
Compare payment profiles
Leica Microsystems (Schweiz) AG
$553.3K 18 recipients
Compare payment profiles
Expanding Innovations, Inc.
$566.5K 92 recipients
Compare payment profiles
Republic Spine
$567.3K 45 recipients
Compare payment profiles
Put this to use
Aesculap Biologics, LLC ranks #738 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Aesculap Biologics, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.